Results 251 to 260 of about 160,832 (337)

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, Volume 158, Issue 2, Page 382-408, 15 January 2026.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source

Gemcitabine and Cisplatin Plus Polymeric Micellar Paclitaxel and Survival in Advanced Biliary Tract Cancer: A Randomized Clinical Trial.

JAMA Netw Open
Jeong H, Yoo C, Kim I, Kang JH, Jeong JH, Park K, Oh SB, Park I, Sym SJ, Cheon J, Ryu H, Hwang JE, Lee JS, Ryoo BY, Kim KP.   +14 more
europepmc   +1 more source

The CXCR1 as a putative marker for cancer stem cell-like phenotypes in chemotherapy-resistant pancreatic ductal adenocarcinoma. [PDF]

Am J Cancer Res
Molczyk C, Sturgeon R, Thomas E, Singh RK.   +3 more
europepmc   +1 more source

Salvage Therapy of Gemcitabine Plus Endostar Significantly Improves Progression-free Survival (PFS) with Platinum-resistant Recurrent Epithelial Ovarian Cancer

, 2013
An Ping Su, Jing Zhang, Zhiren Pan, Qiming Zhou, Xia Lv   +4 more
openalex   +2 more sources

CD30 as a Target Molecule in the Diagnosis and Therapy of Lymphomas

American Journal of Hematology, Volume 101, Issue 1, Page 110-128, January 2026.
ABSTRACT The tumor necrosis factor (TNF)‐receptor superfamily 8 receptor CD30 molecule is expressed in all tumor cells of Hodgkin lymphoma and anaplastic large cell lymphoma but is only weakly expressed in a small subset of large lymphoid cells in normal peripheral lymphoid tissues.
Harald Stein, Brunangelo Falini
wiley   +1 more source

Real-world effectiveness of durvalumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin in advanced gallbladder cancer: a study using the TriNetX global network. [PDF]

Ther Adv Med Oncol
Lin HC, Tseng KY, Shih YH.
europepmc   +1 more source

Salvage Surgery for Primary Renal Pelvic Urothelial Carcinoma After Enfortumab Vedotin: A Case of Durable Remission With Nectin‐4 Loss

IJU Case Reports, Volume 9, Issue 1, January 2026.
ABSTRACT Introduction Enfortumab vedotin is a standard therapy for advanced urothelial carcinoma, but its efficacy may be limited by acquired resistance and spatial heterogeneity of Nectin‐4 expression. Case Presentation We report the case of a 76‐year‐old woman with cT3N2M0 left renal pelvic urothelial carcinoma that was treated with first‐line ...
Takahito Wakamiya, Yuya Iwahashi, Hiroki Kawabata, Satoshi Muraoka, Shimpei Yamashita, Fumiyoshi Kojima, Yasuo Kohjimoto   +6 more
wiley   +1 more source

TRANSPIRE-DRP: a deep learning framework for translating patient-derived xenograft drug response to clinical patients via domain adaptation. [PDF]

J Transl Med
Yang J, Wu T, Xue F, Gong J, Niu X.
europepmc   +1 more source

Staging metastatic urothelial cancer with Nectin‐4 imaging using Gallium‐68‐N188 PET/CT

BJU International, Volume 137, Issue 1, Page 166-172, January 2026.
Objective To quantify Nectin‐4 expression in tumour lesions using the Nectin‐4‐binding peptide Gallium‐68‐N188 and positron emission tomography (PET)/computed tomography (CT) in patients with advanced or metastasised urothelial cancer eligible for therapy with the Nectin‐4‐directed antibody–drug conjugate enfortumab vedotin, in combination with ...
Matthias Miederer, Marc Pretze, Elena Abbate, Andreas Hartig, Joana do Mar Ferreira Machado, Katharina Böhm, Ulrich Sommer, Sebastian Hoberück, Ralph A. Bundschuh, Jörg Kotzerke, Christian Thomas   +10 more
wiley   +1 more source

Surgery based on resectability status of pancreatic cancer: a narrative review. [PDF]

Jpn J Clin Oncol
Einama T, Ohara M, Ichio K, Kobayashi K, Shinada H, Yonamine N, Tsunenari T, Takao M, Takihata Y, Ueno H, Kishi Y.   +10 more
europepmc   +1 more source